SGMO
- Sangamo Therapeutics, Inc.
()
Overview
Company Summary
Sangamo Therapeutics, Inc. (SGMO) is a biotechnology company that focuses on developing genomic medicines to treat various diseases. The company specializes in gene editing and gene therapy technologies.
Sangamo utilizes a unique and proprietary platform called zinc finger nuclease (ZFN) technology, which enables precise editing of the genome in living cells. This technology allows them to modify specific genes or DNA segments to correct or optimize their function.
The company's main therapeutic approach involves using gene editing to address genetic diseases caused by a single gene mutation. By targeting and modifying the faulty gene, Sangamo aims to restore normal function and potentially provide long-term treatment or even cure for these conditions.
Sangamo Therapeutics also focuses on gene regulation, another aspect of their gene-editing capabilities. Through genetic modifications, they aim to control gene expression, turning genes on or off as needed. This approach has various applications, including the potential treatment of diseases where gene regulation plays a critical role.
In addition to their internal pipeline of programs, Sangamo Therapeutics collaborates with pharmaceutical companies to explore the use of their gene-editing technologies in various therapeutic areas. These collaborations help maximize the potential of their technologies and accelerate the development and commercialization of novel treatments.
Overall, Sangamo Therapeutics is dedicated to advancing genomic medicine and improving patient outcomes by editing and regulating genes to address a wide range of diseases and conditions.